<scp>FGFR</scp>2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers <i>in vitro</i>
Yongjun Cha(Seoul National University), Tae‐You Kim(Seoul National University of Science and Technology)
Cited by 33
Related Papers
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
|The Lancet Oncology|2024|124
Patient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer
|Molecular Oncology|2021|43
Identifying TP53RK as a key regulator of colorectal cancer survival and a potential therapeutic target
|Scientific Reports|2025|1